



Public Formulary Overview – Saskatchewan

December 2021

Formulation	Trade Name	Coverage
Long-Acting Stimulants	Foquest	Not covered
	Concerta	Covered – No restrictions
	MPH ER / ER-C	Covered
	Vyvanse	Exceptional Drug Status
	For treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals: (a) Where the use of methylphenidate (short or long-acting formulations) or the use of dexamphetamine has not properly controlled the symptoms of the ADHD; OR (b) Who cannot swallow tablets/capsules whole and require a dissolvable form of a long-acting ADHD medication.	
	Biphentin	
	For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals: (a) Where the use of an another (short or long-acting) formulation has not properly controlled the symptoms of ADHD; or (b) Who cannot swallow tablets/capsules whole and require a long-acting ADHD medication	
	Adderall XR	Not Covered
Short Acting Stimulants	Ritalin	Covered
	Ritalin SR	
	Dexedrine	
	Dexedrine Spansules	
Non-Stimulant Medications	Strattera	Exceptional Drug Status
	For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals who meet all of the following criteria: 1) Have failed, or are intolerant to treatment with methylphenidate and an amphetamine. 2) Treatment with atomoxetine has been recommended by, or in consultation, with a specialist in psychiatry, pediatrics or a general practitioner with expertise in ADHD.	
	Intuniv XR	Not covered

*Information retrieved from the province of Saskatchewan in December 2021, [click here](#) to access the most up to date coverage information. Please review the [Exceptional Drug Status](#) page for detailed information when applicable.